{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:28:30Z","timestamp":1761766110254,"version":"3.37.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1124\/jpet.116.235002","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T01:58:30Z","timestamp":1471053510000},"page":"151-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sphingosine-1-Phosphate (S1P) Lyase Inhibition Causes Increased Cardiac S1P Levels and Bradycardia in Rats"],"prefix":"10.1016","volume":"359","author":[{"given":"Christopher M.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Mittelstadt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Banfor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Duignan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Gintant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngjae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Segreti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.235002_bib1","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.bmcl.2016.02.084","article-title":"Creation of a S1P Lyase bacterial surrogate for structure-based drug design","volume":"26","author":"Argiriadi","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.116.235002_bib2","doi-asserted-by":"crossref","first-page":"8650","DOI":"10.1021\/jm101183p","volume":"53","author":"Bagdanoff","year":"2010","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.235002_bib3","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1021\/jm900278w","article-title":"Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders","volume":"52","author":"Bagdanoff","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.235002_bib4","doi-asserted-by":"crossref","first-page":"e59630","DOI":"10.1371\/journal.pone.0059630","article-title":"Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis","volume":"8","author":"Billich","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/jpet.116.235002_bib5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jcb.22507","article-title":"Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate","volume":"109","author":"Bode","year":"2010","journal-title":"J Cell Biochem"},{"key":"10.1124\/jpet.116.235002_bib6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1194\/jlr.M028084","article-title":"Sphingosine-1-phosphate lyase expression in embryonic and adult murine tissues","volume":"53","author":"Borowsky","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.116.235002_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.116.235002_bib8","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.235002_bib9","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0021-9258(17)33697-9","article-title":"In vivo metabolism of 4\u2032-deoxypyridoxine in rat and man","volume":"251","author":"Coburn","year":"1976","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.235002_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.116.235002_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","article-title":"Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs","volume":"30","author":"Cyster","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1124\/jpet.116.235002_bib12","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.bmcl.2016.03.043","article-title":"Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors","volume":"26","author":"Dinges","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"Suppl 10","key":"10.1124\/jpet.116.235002_bib13","first-page":"2593","article-title":"The oral S1P lyase inhibitor LX3305 (LX2931) demonstrates favorable safety and potential clinical benefit at 12-weeks in a phase 2 proof-of-concept trial in patients with active rheumatoid arthritis on stable methotrexate therapy (Abstract)","volume":"63","author":"Fleischmann","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.116.235002_bib14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1124\/jpet.103.062828","article-title":"Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes","volume":"309","author":"Forrest","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.235002_bib15","doi-asserted-by":"crossref","first-page":"e52985","DOI":"10.1371\/journal.pone.0052985","article-title":"The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P\u2081) and hypertension (S1P\u2083) in rat","volume":"7","author":"Fryer","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.116.235002_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.116.235002_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bbalip.2008.07.003","article-title":"The vascular S1P gradient-cellular sources and biological significance","volume":"1781","author":"Hla","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.116.235002_bib18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.116.235002_bib19","doi-asserted-by":"crossref","first-page":"R440","DOI":"10.1152\/ajpregu.00085.2006","article-title":"Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice","volume":"292","author":"Lorenz","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.116.235002_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"10.1124\/jpet.116.235002_bib21","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1021\/jm900309j","article-title":"1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity","volume":"52","author":"Miller-Moslin","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.235002_bib22","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/jnnp-2013-307538","article-title":"Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?","volume":"85","author":"Mori","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/jpet.116.235002_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0008-6363(03)00260-8","article-title":"Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2","volume":"58","author":"Ohmori","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1124\/jpet.116.235002_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1538-7836.2004.0562h.x","article-title":"Platelet-derived sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2","volume":"2","author":"Ohmori","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1124\/jpet.116.235002_bib25","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1002\/eji.201344158","article-title":"Sphingosine-1-phosphate lyase is expressed by CD68+ cells on the parenchymal side of marginal reticular cells in human lymph nodes","volume":"44","author":"Park","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1124\/jpet.116.235002_bib26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/jcb.21665","article-title":"S1P-lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake","volume":"104","author":"Peest","year":"2008","journal-title":"J Cell Biochem"},{"key":"10.1124\/jpet.116.235002_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1084\/jem.20091619","article-title":"Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning","volume":"207","author":"Pham","year":"2010","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.116.235002_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/00498259009046870","article-title":"Effect of pyridoxine on the disposition and lymphopenic effects of 2-acetyl-4(5)-tetrahydroxybutyl imidazole in the rat","volume":"20","author":"Phillips","year":"1990","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.116.235002_bib29","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1074\/jbc.M311743200","article-title":"Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate","volume":"279","author":"Sanna","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.235002_bib30","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1126\/science.1113640","article-title":"Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients","volume":"309","author":"Schwab","year":"2005","journal-title":"Science"},{"key":"10.1124\/jpet.116.235002_bib31","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.116.235002_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1254\/jjp.82.338","article-title":"Effects of sphingosine 1-phosphate, a naturally occurring biologically active lysophospholipid, on the rat cardiovascular system","volume":"82","author":"Sugiyama","year":"2000","journal-title":"Jpn J Pharmacol"},{"key":"10.1124\/jpet.116.235002_bib33","doi-asserted-by":"crossref","first-page":"e4112","DOI":"10.1371\/journal.pone.0004112","article-title":"Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions","volume":"4","author":"Vogel","year":"2009","journal-title":"PLoS One"},{"key":"10.1124\/jpet.116.235002_bib34","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1021\/jm500338n","article-title":"Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis","volume":"57","author":"Weiler","year":"2014","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.235002_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2014.09.006","article-title":"Analysis of onset mechanisms of a sphingosine 1-phosphate receptor modulator fingolimod-induced atrioventricular conduction block and QT-interval prolongation","volume":"281","author":"Yagi","year":"2014","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652419413X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652419413X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.235002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:48:23Z","timestamp":1739994503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652419413X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S002235652419413X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.235002","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sphingosine-1-Phosphate (S1P) Lyase Inhibition Causes Increased Cardiac S1P Levels and Bradycardia in Rats","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.235002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}